The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System

被引:213
作者
Pratt, Nicole L. [1 ]
Kerr, Mhairi [1 ]
Barratt, John D. [1 ]
Kemp-Casey, Anna [1 ]
Ellett, Lisa M. Kalisch [1 ]
Ramsay, Emmae [1 ]
Roughead, Elizabeth Ellen [1 ]
机构
[1] Univ South Australia, Qual Use Med & Pharm Res Ctr, Adelaide, SA, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
CHRONIC DISEASE SCORE; CO-MORBIDITY; POPULATION; PREVALENCE; MORTALITY; COSTS;
D O I
10.1136/bmjopen-2017-021122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To provide a map of Anatomical Therapeutic Chemical (ATC) Classification System codes to individual Rx-Risk comorbidities and to validate the Rx-Risk Comorbidity Index. Design The 46 comorbidities in the Rx-Risk Index were mapped to dispensing's indicative of each condition using ATC codes. Prescription dispensing claims in 2014 were used to calculate the Rx-Risk. A baseline logistic regression model was fitted using age and gender as covariates. Rx-Risk was added to the base model as an (1) unweighted score, (2) weighted score and as (3) individual comorbidity categories indicating the presence or absence of each condition. The Akaike information criterion and c-statistic were used to compare the models. Setting Models were developed in the Australian Government Department of Veterans' Affairs health claims data, and external validation was undertaken in a 10% sample of the Australian Pharmaceutical Benefits Scheme Data. Participants Subjects aged 65 years or older. Outcome measures Death within 1 year (eg, 2015). Results Compared with the base model (c-statistic 0.738, 95% CI 0.734 to 0.742), including Rx-Risk improved prediction of mortality; unweighted score 0.751, 95% CI 0.747 to 0.754, weighted score 0.786, 95% CI 0.782 to 0.789 and individual comorbidities 0.791, 95% CI 0.788 to 0.795. External validation confirmed the utility of the weighted index (c-statistic=0.833). Conclusions The updated Rx-Risk Comorbidity Score was predictive of 1-year mortality and may be useful in practice to adjust for confounding in observational studies using medication claims data.
引用
收藏
页数:8
相关论文
共 18 条
[1]  
[Anonymous], METHODOLOGY
[2]  
Australian Government Department of Health, 2017, SCHED PHARM BEN
[4]   Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts [J].
Caughey, Gillian E. ;
Roughead, Elizabeth E. ;
Vitry, Agnes I. ;
McDermott, Robyn A. ;
Shakib, Sepehr ;
Gilbert, Andrew L. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (03) :385-393
[5]   Prevalence of comorbidity of chronic diseases in Australia [J].
Caughey G.E. ;
Vitry A.I. ;
Gilbert A.L. ;
Roughead E.E. .
BMC Public Health, 8 (1)
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   A CHRONIC DISEASE SCORE WITH EMPIRICALLY DERIVED WEIGHTS [J].
CLARK, DO ;
VONKORFF, M ;
SAUNDERS, K ;
BALUCH, WM ;
SIMON, GE .
MEDICAL CARE, 1995, 33 (08) :783-795
[8]   Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[9]   PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE [J].
FEINSTEIN, AR .
JOURNAL OF CHRONIC DISEASES, 1970, 23 (07) :455-+
[10]  
Hosmer W., 2000, Applied Logistic Regression, VSecond